



CAPLIN POINT LABORATORIES LTD.

CIN : L24231TN1990PLC019053

Regd. Off. : "NARBAVI", No.3, Lakshmanan Street, T. Nagar, Chennai - 600 017. Tamil Nadu, India. Phone : +91 44 28156653, 28156905
Fax : +91 44 28154952 E-mail : info@caplinpoint.net Website : www.caplinpoint.net

09.11.2016

BSE Limited
Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building.
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code : 524742

By BSE Listing

National Stock Exchange of India Ltd.,
Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G,
Bandra Kurla Complex,
Bandra (E)
Mumbai – 400 051
Scrip Code : CAPLIPOINT.

By NEAPS

Dear Sirs,

SUB: UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / HALF YEAR ENDED SEPTEMBER 30,2016

The Board of Directors of the Company at their meeting held today, have approved the unaudited Financial Results of the Company for the quarter/half year ended September 30,2016. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Unaudited Financial Results of the Company for the quarter/half year ended September 30,2016 together with the limited review report.

Kindly acknowledge its receipt.

Thanking You,

Yours Faithfully,
For Caplin Point Laboratories Limited


Company Secretary
Enclosures : As above

Unit I : No: 85/3, Suthukeny Village, Mannadipet Commune, Puducherry - 605 502. Ph.: +91 413 2674046 / 4047

Unit II : No.19, Chinnapuliur Village, Sirupuzhalpettai (Post), Gummidipoondi Taluk, Thiruvallur District. Pincode - 601 201. Ph.: +91 44 27900901

Unit III : KHASRA No.435,Village Suraj Majra, N.H. No.21,Baddi, Tei. Nalagarh, District Solan, Himachal Pradesh - 173205. Ph.: +91 1795 245512

Unit IV: Survey No.: 895 & 897, Guruvarajakandigai, Sirupuzhalpettai (Post) , Gummidipoondi Taluk, Thiruvallur District, Pincode - 601 201.

Ph.: +9197884 59333/69333



CNGSN & ASSOCIATES LLP
CHARTERED ACCOUNTANTS

No. 43, (Old No. 22), Swathi Court, Flat No. C & D,
Vijayaraghava Road, T. Nagar, Chennai - 600 017.
Tel : +91-44-4554 1480 / 81; Fax : +91-44-4554 1482
Web : www.cngsn.com ; Email : info@cngsn.com

S. NEELAKANTAN
B.Com., FCA

R. THIRUMALMARUGAN
M.Com., FCA

B. RAMAKRISHNAN
B.Com., Grad. CWA, FCA

V. VIVEK ANAND
B.Com., FCA

K. PARTHASARATHY
B.Com., FCA

Dr. C.N. GANGADARAN
B.Com., FCA, MBIM (Lond.), Ph.d.

G. CHELLA KRISHNA
M.Com., FCA, PGPM

D. KALAIALAGAN
B.Com., FCA

NYAPATHY SRILATHA
M.Com., FCA, PGDFM

E.K. SRIVATSAN
B.Com., FCA

Limited Review Report on Quarterly Standalone Financials Results of Caplin Point Laboratories Limited pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015

To
The Board of Directors
Caplin point Laboratories Limited

We have reviewed the accompanying statement of unaudited standalone financial results (' the Statement') of **Caplin Point Laboratories Limited** for the quarter ended 30 September 2016, being submitted by the company pursuant of the requirements of regulations 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations,2015.

This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue report on these financials statements based on our review.

We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e., Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and other recognised accounting practices and policies has not disclosed the information



required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and SEBI Circular dated 05 July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Chennai
Date : November 9,2016



For M/s CNGSN & ASSOCIATES LLP
CHARTERED ACCOUNTANTS
Firm Registration No: 0049155/S200036

B. Ramakrishnan

B.RAMAKRISHNAN
Partner
Membership No:201023

CAPLIN POINT LABORATORIES LIMITED

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017

C IN - 124231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

UNAUDITED (STANDALONE) FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30.09.2016

Part I	Particulars	Quarter Ended			Half Year Ended		9 Months period and Financial Year ended
		30.09.2016 (1)	30.06.2016 (2)	30.09.2015 (3)	30.09.2016 (4)	30.09.2015 (5)	31.03.2016 (6)
		(Unaudited)					(Audited)
		Rs. In Lakhs					
1	Income						
	a. Net Sales/ income from operations (Net of Excise Duty)	8132.10	7720.09	7432.79	15,852.19	13,950.13	22,704.36
	b. Foreign Exchange Fluctuation Gain	29.29	-	-	29.29	-	-
	c. Share of profits in LLP	100.63	235.00	116.03	335.63	353.87	424.86
	d. Total	8262.02	7955.09	7548.82	16217.11	14304.00	23129.22
2	Expenditure						
	a. Cost of materials consumed	1694.95	1744.45	1058.02	3,439.40	2,058.61	3,897.53
	b. Purchase of Stock-in-Trade	2354.03	2450.37	2797.05	4,804.40	5,328.12	7,806.63
	c. Change in inventories of Finished Goods, work in progress and stock in trade	42.67	(35.68)	136.38	6.99	(22.50)	(30.82)
	d. Employees benefit expenses	692.94	638.41	533.91	1,331.35	1,069.25	1,757.04
	e. Depreciation & Amortisation Expenses	259.41	266.28	209.80	525.69	518.44	729.91
	f. Foreign Exchange Fluctuation Loss	-	2.95	89.86	2.95	178.81	321.83
	g. Other Expenditure	1282.63	1,117.63	878.59	2,400.26	1,784.71	3,089.69
	h. Total Expenses	6,326.64	6,184.41	5,703.61	12,511.05	10,915.44	17,571.81
3	Profit(+)/Loss(-) before other income and finance cost (1-2)	1,935.38	1,770.68	1,845.21	3,706.06	3,388.56	5,557.41
4	Other Income	162.79	131.87	79.05	294.66	163.21	347.32
5	Profit(+)/Loss(-) before finance costs and Tax (3+4)	2,098.17	1,902.55	1,924.26	4,000.72	3,551.77	5,904.73
6	Finance cost	5.07	2.37	2.99	7.44	12.60	10.82
7	Profit(+)/Loss(-) before Tax (5-6)	2,093.10	1,900.18	1,921.27	3,993.28	3,539.17	5,893.91
8	Provision for Taxation	495.33	383.19	446.07	878.52	803.81	1,264.71
	Provision for Taxation - earlier years	-	-	-	-	-	-
	Deferred Tax Provision	(84.69)	74.81	55.36	(9.88)	45.84	264.11
	Mat Credit Entitlement	-	-	-	-	-	(223.41)
9	Net Profit(+)/Loss(-) for the period (7-8)	1,682.45	1,442.18	1,419.84	3,124.64	2,689.52	4,588.50
10	Other Comprehensive Income	0.22	1.68	0.20	1.90	0.21	(59.48)
11	Total Comprehensive Income(9+10)	1,682.67	1,443.86	1,420.04	3,126.54	2,689.73	4,529.02
12	Paid up Equity Share Capital (Face value of the share - Rs 10/- each)	1511.00	1511.00	1511.00	1,511.00	1,511.00	1,511.00
13	Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year						11,573.96
14	Earnings/(Loss) Per Share (EPS) (Not annualised) based on face value Rs 10/- per Equity share (prior to sub division of shares)						
	(a) Basic/Diluted EPS before Extraordinary items (in Rupees)	11.14	9.54	8.40	20.69	17.80	29.99
	(b) Basic/Diluted EPS after Extraordinary items (in Rupees)	11.14	9.54	8.40	20.69	17.80	29.99
	Earnings/(Loss) Per Share (EPS) (Not annualised) based on face value Rs 2/- per Equity share (post sub division of shares)						
	(a) Basic/Diluted EPS before Extraordinary items (in Rupees)	2.23	1.91	1.88	4.14	3.56	5.99
	(b) Basic/Diluted EPS after Extraordinary items (in Rupees)	2.23	1.91	1.88	4.14	3.56	5.99

Part II		Select information for the quarter ended 30th September 2016			
		Three months ended			9 months period ended
		September 2016	June 2016	September 2015	March 2016
A	PARTICULARS OF SHARE HOLDING				
15	Public Shareholding				
	- Number of Shares	4671247	4671247	4863247	4863247
	- Percentage of Shareholding	30.91%	30.91%	32.19%	32.19%
16	Promoters and promoter group Shareholding				
	a) Pledged/Encumbered				
	- Number of Shares	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)				
	- Percentage of shares (as a % of the total share capital of the company)				
	b) Non-encumbered				
	- Number of Shares	10438753	10438753	10246753	10246753
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the company)	69.09%	69.09%	67.81%	67.81%

B	Particulars	3 months ended 30-09-2016
	INVESTOR COMPLAINTS	Nos
	Pending at the beginning of the quarter	1
	Received during the quarter	72
	Disposed of during the quarter	69
	Remaining unresolved at the end of the quarter	4

Notes :

- 1) The above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 09 November 2016.
- 2) Statutory Auditors have carried out Limited Review of the financial results for the quarter and half year ended 30th September 2016.
- 3) The Ind AS compliant corresponding figures for the half year ended 30th September 2016 and financial year ended 31 March 2016 and corresponding previous half year ended 30th September 2015 have not been subjected to review/audit. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.

Reconciliation between financial results as previously reported under Previous GAAP and Ind AS for the Half year/Year presented are as under:

Standalone			
Amounts in Indian Rupees Lakhs			
Particulars		For the half year ended 30.09.2015	For the 9 months period and financial year ended 31.03.2016
Net profit under previous GAAP		2,689.52	4,532.53
Actuarial (gain) / Loss on employee defined benefit funds recognised in Other Comprehensive income		-	55.95
Net profit for the period under Ind AS		2,689.52	4,588.48
Other Comprehensive Income		0.21	(59.48)
Total Comprehensive Income under Ind AS		2,689.73	4,529.00

- 4) The consolidated interim financial results of the company and its subsidiary have been prepared as per Ind AS 110 on Consolidated Financial Statements
- 5) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary items
- 6) From 1st April 2016, Company has adopted accounting standards notified under Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34
- 7) Under Accounting Standard, financial assets were measured at lower of cost and realisable value. Under Ind AS such financial assets are recognised and measured at fair value. Impact of fair value change as on the date of transition, i.e., 1st April 2015, is recognised in reserves and changes thereafter are recognised in Statement of Profit and Loss or Other Comprehensive Income, as the case may be.
- 8) Employee benefits - Actuarial gains and losses on defined benefit plans: Under Accounting Standard all actuarial gains and losses were recognised in Statement of profit and loss. Under Ind AS these are recognised in Other Comprehensive Income.
- 9) With effect from 20th Oct, 2016 the Equity shares of the Company having face value of Rs 10/- each has been sub divided into 5 shares of Rs 2/- each. Accordingly, number of paid up shares of the Company stand at 7,55,50,000.
- 10) Prior year / period figures are regrouped / rearranged wherever necessary.




Dr. Sridhar Ganesan
Managing Director

Place : Chennai

Date : 09.11.2016

For C N G S N & ASSOCIATES LLP
CHARTERED ACCOUNTANTS
FR No: 0049155 / S200036



B. RAMAKRISHNAN
PARTNER
MEMB.No. 201023

Standalone Balance sheet as at 30th September 2016

INR in Lakhs

Particulars	Unaudited
ASSETS	
(1) Non-Current Assets	
(a) Property, Plant and Equipment	14,140.76
(b) Capital work-in-progress	27.40
(c) Other Intangible assets	53.52
(d) Financial Assets	
(i) Investments	156.53
(e) Other Non-Current Assets	163.92
(2) Current Assets	
(a) Inventories	1,525.76
(b) Financial Assets	
(i) Trade Receivables	1,250.00
(ii) Cash and Cash equivalents	8,897.30
(c) Other Current Assets	2,266.61
	28,481.81
Equity and Liabilities	
(1) Equity	
Equity Share capital	1,511.00
Other Equity	14,429.37
(2) Liabilities	
(A) Non-Current Liabilities	
(a) Financial Liabilities	
(i) Borrowings	56.06
(b) Deferred Tax Liabilities (Net)	1,123.58
(B) Current Liabilities	
(a) Financial Liabilities	
(i) Trade Payables	4,348.26
(b) Other Current Liabilities	6,114.01
(c) Provisions	860.20
(d) Current Tax Liabilities (Net)	39.32
	28,481.81



CNGSN & ASSOCIATES LLP
CHARTERED ACCOUNTANTS

No. 43, (Old No. 22), Swathi Court, Flat No. C & D,
Vijayaraghava Road, T. Nagar, Chennai - 600 017.
Tel : +91-44-4554 1480 / 81; Fax : +91-44-4554 1482
Web : www.cngsn.com ; Email : info@cngsn.com

S. NEELAKANTAN
B.Com., FCA

R. THIRUMALMARUGAN
M.Com., FCA

B. RAMAKRISHNAN
B.Com., Grad. CWA, FCA

V. VIVEK ANAND
B.Com., FCA

K. PARTHASARATHY
B.Com., FCA

Dr. C.N. GANGADARAN
B.Com., FCA, MBIM (Lond.), Ph.d.

G. CHELLA KRISHNA
M.Com., FCA, PGPM

D. KALAIALAGAN
B.Com., FCA

NYAPATHY SRILATHA
M.Com., FCA, PGDFM

E.K. SRIVATSAN
B.Com., FCA

Limited Review Report on Quarterly Consolidated Financial Results of Caplin Point Laboratories Limited pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015


To
The Board of Directors
Caplin point Laboratories Limited

We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of **Caplin Point Laboratories Limited** ("the company"), its subsidiary (the company, its subsidiary constitute "the group") for the quarter ended 30 September 2016, being submitted by the company pursuant to the requirements of regulations 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015.

This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue report on these financials statements based on our review.

We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards i.e., Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of



Regulations 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and SEBI Circular dated 05 July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s CNGSN & ASSOCIATES LLP
CHARTERED ACCOUNTANTS
Firm Registration No: 004915S/S200036

B. Ramakrishnan

B.RAMAKRISHNAN
Partner
Membership No:201023

Place : Chennai
Date :November 09, 2016



CAPLIN POINT LABORATORIES LIMITED

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017

CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

UNAUDITED (CONSOLIDATED) FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30.09.2016

Part I	Particulars	Quarter Ended			Half Year Ended		9 Months period and Financial Year ended
		30.09.2016	30.06.2016	30.09.2015	30.09.2016	30.09.2015	
		(1)	(2)	(3)	(4)	(5)	
(Unaudited)						(Audited)	
Rs. In Lakhs							
1	Income						
	a. Net Sales/ income from operations (Net of Excise Duty)	9,572.20	8507.90	7754.27	18,080.10	14,766.97	23,872.17
	b. Foreign Exchange Fluctuation Gain	32.29	-	-	32.29	-	-
	c. Total	9604.49	8507.90	7754.27	18112.39	14766.97	23872.17
2	Expenditure						
	a. Cost of materials consumed	1694.95	1754.45	1211.55	3,449.40	2,392.26	4,408.34
	b. Purchase of Stock-in-Trade	3045.02	2745.06	2762.35	5,790.08	5,313.04	7,776.16
	c. Change in inventories of Finished Goods, work in progress and stock in trade	57.19	(48.07)	158.52	9.12	3.19	(68.04)
	d. Employees benefit expenses	695.94	644.61	542.41	1,340.55	1,085.77	1,790.72
	e. Depreciation & Amortisation Expenses	259.41	273.28	212.26	532.69	523.41	747.78
	f. Foreign Exchange Fluctuation Loss	-	2.13	83.49	2.13	156.20	293.36
	g. Other Expenditure	1294.68	1,163.45	920.73	2,458.13	1,862.08	3,217.64
	h. Total Expenses	7,047.19	6,534.91	5,891.31	13,582.10	11,335.95	18,165.96
3	Profit(+)/Loss(-) before other income and finance cost (1-2)	2,557.30	1,972.99	1,862.96	4,530.29	3,431.02	5,706.20
4	Other income	167.09	137.12	89.79	304.21	180.94	365.95
5	Profit(+)/Loss(-) before finance costs and Tax (3+4)	2,724.39	2,110.11	1,952.75	4,834.50	3,611.96	6,072.15
6	Finance cost	5.37	3.42	3.02	8.79	12.68	11.01
7	Profit(+)/Loss(-) before Tax (5-6)	2,719.02	2,106.69	1,949.73	4,825.71	3,599.28	6,061.14
8	Provision for Taxation	545.33	418.19	486.07	963.52	873.81	1,430.61
	Provision for Taxation - earlier years	-	-	-	-	-	-
	Deferred Tax Provision	(84.69)	74.81	55.36	(9.88)	45.84	264.11
	Mat Credit Entitlement	-	-	-	-	-	(266.44)
9	Net Profit(+)/Loss(-) for the period (7-8)	2,258.37	1,613.68	1,408.30	3,872.06	2,679.63	4,632.86
10	Other Comprehensive Income	0.22	1.68	0.20	1.90	0.21	(59.48)
11	Total Comprehensive Income(9+10)	2,258.59	1,615.36	1,408.50	3,873.96	2,679.84	4,573.38
12	Minority Interest	2.26	1.61	0.12	3.87	2.52	0.43
13	Net Profit(+)/Loss(-) for the period after minority interest (11-12)	2,256.33	1,613.75	1,408.38	3,870.09	2,677.32	4,572.95
13	Paid up Equity Share Capital (Face value of the share - Rs 10/- each)	1511.00	1511.00	1511.00	1,511.00	1,511.00	1,511.00
14	Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year						11,573.88
15	Earnings/(Loss) Per Share (EPS) (Not annualised)based on face value Rs 10/- per Equity share (prior to sub division of shares)						
	(a) Basic/Diluted EPS before Extraordinary items (in Rupees)	14.93	10.68	9.32	25.61	17.71	30.29
	(b) Basic/Diluted EPS after Extraordinary items (in Rupees)	14.93	10.68	9.32	25.61	17.71	30.29
	Earnings/(Loss) Per Share (EPS) (Not annualised)based on face value Rs 2/- per Equity share(post sub division of shares)						
	(a) Basic/Diluted EPS before Extraordinary items (in Rupees)	2.99	2.14	1.86	5.12	3.54	6.05
	(b) Basic/Diluted EPS after Extraordinary items (in Rupees)	2.99	2.14	1.86	5.12	3.54	6.05

Part II		Select information for the quarter ended 30th September 2016			
		Three months ended			9 months period ended
		September 2016	June 2016	September 2015	March 2016
A	PARTICULARS OF SHARE HOLDING				
15	Public Shareholding				
	- Number of Shares	4671247	4671247	4863247	4863247
	- Percentage of Shareholding	30.91%	30.91%	32.19%	32.19%
16	Promoters and promoter group Shareholding				
	a) Pledged/Encumbered				
	- Number of Shares	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-
	b) Non-encumbered				
	- Number of Shares	10438753	10438753	10246753	10246753
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the company)	69.09%	69.09%	67.81%	67.81%

B	Particulars	3 months ended 30-09-2016
	INVESTOR COMPLAINTS	Nos
	Pending at the beginning of the quarter	1
	Received during the quarter	72
	Disposed of during the quarter	69
	Remaining unresolved at the end of the quarter	4

Notes :

- 1) The above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 09 November 2016.
- 2) Statutory Auditors have carried out Limited Review of the financial results for the quarter and half year ended 30th September 2016.
- 3) The Ind AS compliant corresponding figures for the half year ended 30th September 2016 and financial year ended 31 March 2016 and corresponding previous half year ended 30th September 2015 have not been subjected to review/audit. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.

Reconciliation between financial results as previously reported under Previous GAAP and Ind AS for the Half year /Year presented are as under:

Consolidated			
Amounts in Indian Rupees Lakhs			
Particulars		For the half year ended 30.09.2015	For the 9 months period and financial year ended 31.03.2016
Net profit under previous GAAP		2,679.63	4,576.92
Actuarial (gain) / Loss on employee defined benefit funds recognised in Other Comprehensive income		-	55.95
Net profit for the period under Ind AS		2,679.63	4,632.87
Other Comprehensive Income		0.21	(59.48)
Total Comprehensive Income under Ind AS		2,679.84	4,573.39

- 4) The consolidated interim financial results of the company and its subsidiary have been prepared as per Ind AS 110 on Consolidated Financial Statements
- 5) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary items
- 6) From 1st April 2016, Company has adopted accounting standards notified under Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34
- 7) Under Accounting Standard, financial assets were measured at lower of cost and realisable value. Under Ind AS such financial assets are recognised and measured at fair value. Impact of fair value change as on the date of transition, i.e., 1st April 2015, is recognised in reserves and changes thereafter are recognised in Statement of Profit and Loss or Other Comprehensive Income, as the case may be.
- 8) Employee benefits - Actuarial gains and losses on defined benefit plans: Under Accounting Standard all actuarial gains and losses were recognised in Statement of profit and loss. Under Ind AS these are recognised in Other Comprehensive Income.
- 9) With effect from 20th Oct, 2016 the Equity shares of the Company having face value of Rs 10/- each has been sub divided into 5 shares of Rs 2/- each . Accordingly number of paid up shares of the Company stand at 7,55,50,000.
- 10) Prior year / period figures are regrouped / rearranged wherever necessary.



Dr. Sridhar Ganesan
Managing Director

Place : Chennai
Date : 09.11.2016

For C N G S N & ASSOCIATES LLP
CHARTERED ACCOUNTANTS
FR No: 0049155 / S200036



B. RAMAKRISHNAN
PARTNER
MEMB.No. 201023

Consolidated Balance sheet as at 30th September 2016

Particulars	INR in Lakhs
	Unaudited
ASSETS	
(1) Non-Current Assets	
(a) Property, Plant and Equipment	14,143.79
(b) Capital work-in-progress	27.40
(c) Other Intangible assets	53.52
(d) Financial Assets	
(i) Investments	37.37
(e) Other Non-Current Assets	163.92
(2) Current Assets	
(a) Inventories	1,525.76
(b) Financial Assets	
(i) Trade Receivables	2,424.89
(ii) Cash and Cash equivalents	9,176.51
(c) Other Current Assets	1,158.23
	28,711.39
Equity and Liabilities	
(1) Equity	
Equity Share capital	1,511.00
Other Equity	14,913.83
Minority interest	30.96
(2) Liabilities	
(A) Non-Current Liabilities	
(a) Financial Liabilities	
(i) Borrowings	56.06
(b) Deferred Tax Liabilities (Net)	1,123.58
(B) Current Liabilities	
(a) Financial Liabilities	
(i) Trade Payables	4,012.30
(b) Other Current Liabilities	6,119.39
(c) Provisions	860.20
(d) Current Tax Liabilities (Net)	84.06
	28,711.39